Isavuconazole use and TDM in real-world pediatric practice
Berta Fernández Ledesma, Natalia Mendoza‐Palomar, Susana Melendo, Aurora Fernández-Polo, Berta Renedo, Alba Pau Parra, Sonia Luque Pardos, Santiago Grau Cerrato, Jaume Vima Bofarull, Marı́a Gómez, Montserrat Pujol Jover, María Isabel Benítez‐Carabante, Cristina Díaz de Heredia, Pere Soler‐Palacín
Abstract
ABSTRACT Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) C trough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).